Sales of diabetes medicine in Australia are projected to grow steadily from AUD 1.21 billion in 2024 to AUD 1.52 billion in 2028. This represents a compound annual growth rate (CAGR) of about 5.8% over the five-year period.
The year-on-year growth rates reflect consistent increases: 6.6% from 2024 to 2025, 6.2% from 2025 to 2026, 5.8% from 2026 to 2027, and 4.8% from 2027 to 2028. As of 2023, the baseline for diabetes medicine sales stood at approximately AUD 1.14 billion.
Future trends to watch for include advances in diabetes treatment technologies, potential government policy changes regarding healthcare funding, and the impact of lifestyle-related factors on diabetes prevalence.
